Bliss GVS Pharma Limited

BSE: 506197 NSE: BLISSGVS
Bliss GVS Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1984PLC034771 Incorporated 11 December 1984 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: BLISSGVS · BSE: 506197 Public Limited Company pharma
Data last updated
Market Cap
₹6,965 Cr
BLISSGVS · NSE
Share Price
₹654.75
+4.89% today
Revenue
₹927 Cr
FY 2025-26 · +14.5% YoY
EBITDA
₹162 Cr
Margin 17.4%
Net Profit
₹132 Cr
FY 2025-26 · +56.1% YoY
P/E (TTM)
40.8x
P/B 5.2x
ROE
12.0%
ROCE 17.0%
Debt / Equity
0.05
Interest cover 9.4x

About Bliss GVS Pharma Limited

Data last updated:

Bliss GVS Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 December 1984 and has been in existence for over 42 years.

Its director Narsimha Shibroor Kamath is #1,202 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH1984PLC034771. Its GSTIN is 27AABCB1382J1ZQ (Maharashtra). The company holds 3 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 506197 and NSE: BLISSGVS.

The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹10.62 Cr. It was formerly known as Bliss Gvs Phrma Limited (Cn) and Bliss Chemicals and Pharmaceuticals India Limited. It is led by directors including Shruti Vishal Rao (Whole-Time Director) and Vibha Gagan Sharma (Whole-Time Director).

Its last annual general meeting (AGM) was held on 31 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 102 Hyde Park Sakivihar Road Andheri (East)., Mumbai, Maharashtra, India – 400072.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹927.11 Cr, a growth of 14.5% compared to the previous year. For the same year it recorded a net profit of ₹131.92 Cr (net margin 14.2%) and EBITDA of ₹161.54 Cr (EBITDA margin 17.4%). The net worth stands at ₹1,192.9 Cr (up 13.6% YoY). Total assets are valued at ₹1,265.32 Cr (up 6.8% YoY).

The company has about 926 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Bliss GVS. As per MCA filings, the company has open charges of ₹161 Cr and satisfied charges of ₹401.25 Cr on record. Court records list 51 cases involving the company, including 12 filed by the company and 39 filed against it; 20 cases are pending. The company has 86 deals on record (85 market trades, 1 secondary share transfer); the latest was in September 2026. The company has 15 MSME Form 1 returns on record between 2019 and 2024, listing 1,629 overdue payments to 115 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website blissgvs.com.

Company details

CIN L24230MH1984PLC034771
Registration Number 034771
Incorporation Date 11 December 1984
ROC Mumbai
Listing Status Listed - Listed on NSE (BLISSGVS); Listed on BSE (506197)
Company Status Active
Date of Last AGM 31 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Bliss GVS Pharma has undergone 3 name changes throughout its history. The company was previously known as Bliss Gvs Phrma Limited (Cn), Bliss Chemicals And Pharmaceuticals India Limited, and Bliss Gvs Phrma Limited (Cn). The current legal name is Bliss Gvs Pharma Limited.

Company NameStatus
Bliss GVS Pharma LimitedCurrent
Bliss Gvs Phrma Limited (Cn)Previous
Bliss Chemicals And Pharmaceuticals India LimitedPrevious
Bliss Gvs Phrma Limited (Cn)Previous

CIN history

Bliss GVS Pharma has one previous CIN (Corporate Identification Number): U24230MH1984PTC034771. The current CIN is L24230MH1984PLC034771, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230MH1984PLC034771Current
U24230MH1984PTC034771Previous
Key People
Narsimha Shibroor Kamath Ceo Shruti Vishal Rao Whole-Time Director Vibha Gagan Sharma Whole-Time Director

Recognitions & Rankings of Bliss GVS Pharma

Contact details

Bliss GVS Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is blissgvs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    blissgvs.com
  • Social Media
  • Registered Address
    102 Hyde Park Sakivihar Road Andheri (East)., Mumbai, Maharashtra, India – 400072
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Bliss GVS Pharma Limited, buy the company report.

Comprehensive company report
Bliss GVS Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Bliss GVS Pharma operates one associated brand: Bliss GVS. Each brand links to its own profile.

BrandDescriptionWebsite
Bliss GVS
Pharmaceutical products including suppositories and pessaries are manufactured.blissgvs.com

Business activity

The main business activity of Bliss GVS Pharma is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Bliss GVS Pharma Limited, buy the company report.

Financials of Bliss GVS Pharma Limited

FY 2025-26 filings available

Bliss GVS Pharma Limited reported revenue of ₹927.11 Cr (up 14.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹927 Cr
+14.5% YoY
EBITDA
₹162 Cr
+27.5% YoY
Profit After Tax
₹132 Cr
+56.1% YoY
Net Worth
₹1,193 Cr
+13.6% YoY
Total Assets
₹1,265 Cr
+6.8% YoY
Total Debt
₹21.75 Cr
-75.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue927810770752747577689
Revenue growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-
EBITDA16212712111744.74107110
EBITDA margin+17.4%+15.7%+15.8%+15.6%+6.0%+18.5%+16.0%
Profit before tax19012611710654.16104129
Net profit13284.4995.8670.6435.4368.53106
Net profit margin+14.2%+10.4%+12.5%+9.4%+4.7%+11.9%+15.4%
EPS (₹)12.218.007.216.801.456.649.43
Balance sheet
Total assets1,2651,1841,1061,022957952879
Net worth1,1931,050967884819808736
Total debt21.7588.1099.84102109122126
Cash & bank167213216103178145103
Net working capital718707708558626649625
Cash flow
Cash from operations13910610334.3113563.9746.70
Cash from investing(38.18)(75.49)(83.34)(6.36)(103)(45.38)(40.09)
Cash from financing(89.21)(30.20)(20.89)(24.94)(23.73)(20.80)(6.30)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue313286257218244207198210
Revenue growth (YoY)+28.2%+37.7%+29.8%+3.7%+12.3%+13.0%--
Other income8.309.6011.1918.468.4635.4512.0715.27
EBITDA80.5976.4044.4432.2743.4841.3321.0929.79
EBITDA margin+25.7%+26.8%+17.3%+14.8%+17.8%+19.9%+10.7%+14.2%
Depreciation10.509.948.678.358.268.208.047.55
Interest3.300.582.011.493.045.471.681.08
Profit before tax75.0975.4844.9540.8940.6463.1123.4436.43
Tax21.7624.117.9516.1212.0418.746.7910.62
Net profit53.3351.3737.0024.7728.6044.3716.6525.81
EPS (₹)4.814.653.282.142.544.041.462.27
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue730667605598636466442
Revenue growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%-
EBITDA13291.5866.0990.1510991.46100
EBITDA margin+18.1%+13.7%+10.9%+15.1%+17.2%+19.7%+22.7%
Profit before tax13394.1770.2611612691.19122
Net profit98.1369.1176.1185.2290.5967.5391.81
Net profit margin+13.5%+10.4%+12.6%+14.2%+14.2%+14.5%+20.8%
EPS (₹)9.166.554.848.218.946.548.95
Balance sheet
Total assets1,1801,1311,0691,020942850778
Net worth1,1551,059988937851756683
Total debt13.2367.7277.5080.5789.9191.8493.09
Cash & bank11117116984.6114912086.62
Net working capital662676691614662588572
Cash flow
Cash from operations12397.2182.1743.8111466.9763.22
Cash from investing(51.30)(77.97)(65.84)(12.97)(92.28)(61.62)(60.14)
Cash from financing(75.37)(26.56)(20.76)(26.05)(12.62)(11.67)(5.83)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue261222212165190163156180
Revenue growth (YoY)+37.3%+35.7%+35.6%-8.3%+4.2%+9.7%--
Other income48.528.769.6610.2313.5910.599.3611.66
Total expenses201170167140160131142154
EBITDA60.4451.8744.1524.3430.2732.7613.7325.73
EBITDA margin+23.1%+23.4%+20.9%+14.8%+15.9%+20.1%+8.8%+14.3%
Depreciation9.479.037.847.807.697.687.436.96
Interest1.120.391.811.482.715.111.300.67
Profit before tax98.3751.2144.1625.2933.4630.5614.3629.76
Tax24.8012.5911.746.688.669.512.918.72

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue313286257218244207198210
Revenue growth (YoY)+28.2%+37.7%+29.8%+3.7%+12.3%+13.0%--
Other income8.309.6011.1918.468.4635.4512.0715.27
EBITDA80.5976.4044.4432.2743.4841.3321.0929.79
EBITDA margin+25.7%+26.8%+17.3%+14.8%+17.8%+19.9%+10.7%+14.2%
Depreciation10.509.948.678.358.268.208.047.55
Interest3.300.582.011.493.045.471.681.08
Profit before tax75.0975.4844.9540.8940.6463.1123.4436.43
Tax21.7624.117.9516.1212.0418.746.7910.62
Net profit53.3351.3737.0024.7728.6044.3716.6525.81
EPS (₹)4.814.653.282.142.544.041.462.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue927810770752747577689
Revenue growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-
Other income73.5336.4928.7417.7931.4920.2239.19
Total expenses766683649634703471579
Employee cost13611295.5886.1776.1568.0953.69
EBITDA16212712111744.74107110
EBITDA margin+17.4%+15.7%+15.8%+15.6%+6.0%+18.5%+16.0%
Depreciation33.4829.4226.3818.6717.3317.2312.59
Interest12.018.126.9110.364.745.517.57
Profit before tax19012611710654.16104129
Tax54.8635.3935.2929.3431.0430.1533.72
Net profit13284.4995.8670.6435.4368.53106
Net profit margin+14.2%+10.4%+12.5%+9.4%+4.7%+11.9%+15.4%
EPS (₹)12.218.007.216.801.456.649.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5810.5410.4710.4210.3710.3110.31
Reserves & surplus1,1821,040957873808798725
Shareholders' funds (net worth)1,1931,050967884819808736
Minority interest38.8641.4735.7933.5327.7619.6614.76
Secured loans2.9370.9762.5671.3668.3197.64104
Unsecured loans18.8217.1337.2830.5441.0824.2622.50
Total debt21.7588.1099.84102109122126
Total liabilities1,2651,1841,1061,022957952879
Assets
Gross block608532468459344286277
Net block459406370379281234242
Capital work in progress6.0520.717.832.8022.152.390.00
Investments4.974.384.177.802.390.010.02
Inventories15112611810312498.9376.92
Sundry debtors517439404385393464548
Cash & bank balances167213216103178145103
Loans & advances11045.9971.9010182.6457.9144.37
Total current assets945824810692777765773
Total current liabilities227117102135150116147
Net working capital718707708558626649625
Total assets1,2651,1841,1061,022957952879
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash23.8223.5925.0121.9913.1315.3415.04
Net cash from operating activities13910610334.3113563.9746.70
Net cash from investing activities(38.18)(75.49)(83.34)(6.36)(103)(45.38)(40.09)
Net cash from financing activities(89.21)(30.20)(20.89)(24.94)(23.73)(20.80)(6.30)
Net change in cash11.320.23(1.42)3.028.85(2.21)0.30
Closing cash167213216103178145103
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-
EBITDA growth+27.5%+4.3%+3.5%+162.2%-58.1%-3.0%-
PBT growth+50.9%+7.5%+10.2%+95.9%-48.0%-19.3%-29.1%
Net income growth+56.1%-11.9%+35.7%+99.4%-48.3%-35.5%-
Revenue CAGR (3Y)+7.3%+2.7%+10.1%+2.9%-6.0%-10.9%-4.8%
EBITDA CAGR (3Y)+11.3%+41.5%+4.4%+2.2%-34.3%-13.2%-18.5%
Profitability & leverage
Net income margin+14.5%+11.2%+10.6%+10.2%+3.1%+12.8%+13.8%
Return on capital employed+17.0%+12.1%+14.8%+12.1%+14.2%+12.2%+16.9%
Return on net worth+12.0%+9.0%+11.0%+9.0%+5.4%+9.6%+13.8%
Debt / equity0.050.090.110.120.140.160.17
Long-term debt / equity0.020.040.050.040.040.050.05
Interest cover9.388.357.2710.5017.296.167.78
Efficiency & per share
Fixed asset turnover1.631.621.661.872.372.053.08
Inventory turnover6.716.636.956.626.716.568.94
Debtors turnover1.941.921.951.931.751.141.37
EPS (₹)12.218.007.216.801.456.649.43
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)112.7699.6892.3884.8778.9778.3671.32
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue261222212165190163156180
Revenue growth (YoY)+37.3%+35.7%+35.6%-8.3%+4.2%+9.7%--
Other income48.528.769.6610.2313.5910.599.3611.66
Total expenses201170167140160131142154
EBITDA60.4451.8744.1524.3430.2732.7613.7325.73
EBITDA margin+23.1%+23.4%+20.9%+14.8%+15.9%+20.1%+8.8%+14.3%
Depreciation9.479.037.847.807.697.687.436.96
Interest1.120.391.811.482.715.111.300.67
Profit before tax98.3751.2144.1625.2933.4630.5614.3629.76
Tax24.8012.5911.746.688.669.512.918.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue730667605598636466442
Revenue growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%-
Other income43.7236.2233.5050.7735.3717.6837.00
Total expenses598576539508527374342
Employee cost12299.4282.5972.5465.0658.6144.02
EBITDA13291.5866.0990.1510991.46100
EBITDA margin+18.1%+13.7%+10.9%+15.1%+17.2%+19.7%+22.7%
Depreciation31.0227.0523.5215.1713.8513.768.83
Interest11.116.585.8110.064.324.196.62
Profit before tax13394.1770.2611612691.19122
Tax36.5925.2019.6230.2133.7323.6829.37
Net profit98.1369.1176.1185.2290.5967.5391.81
Net profit margin+13.5%+10.4%+12.6%+14.2%+14.2%+14.5%+20.8%
EPS (₹)9.166.554.848.218.946.548.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5810.5410.4710.4210.3710.3110.31
Reserves & surplus1,1451,048978927841745673
Shareholders' funds (net worth)1,1551,059988937851756683
Secured loans0.0023.1045.8365.7164.6967.8771.49
Unsecured loans13.2344.6231.6714.8625.2223.9721.60
Total debt13.2367.7277.5080.5789.9191.8493.09
Total liabilities1,1801,1311,0691,020942850778
Assets
Gross block555478414386270212203
Net block420369331326225175180
Capital work in progress4.4020.587.832.8022.152.390.00
Investments18.6918.6918.6918.2618.2618.3018.31
Inventories11181.9489.4574.1590.1183.6860.57
Sundry debtors457429400399409349405
Cash & bank balances11117116984.6114912086.62
Loans & advances14883.9911417214312590.55
Total current assets826766772730792677643
Total current liabilities16489.4281.7211613088.5970.94
Net working capital662676691614662588572
Total assets1,1801,1311,0691,020942850778
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.8514.1718.6013.824.6711.0013.75
Net cash from operating activities12397.2182.1743.8111466.9763.22
Net cash from investing activities(51.30)(77.97)(65.84)(12.97)(92.28)(61.62)(60.14)
Net cash from financing activities(75.37)(26.56)(20.76)(26.05)(12.62)(11.67)(5.83)
Net change in cash(3.52)(7.32)(4.43)4.799.14(6.33)(2.75)
Closing cash11117116984.6114912086.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%-
EBITDA growth+44.0%+38.6%-26.7%-17.5%+19.4%-8.7%-
PBT growth+41.7%+34.0%-39.3%-8.5%+38.6%-25.1%+1.4%
Net income growth+42.0%-9.2%-10.7%-5.9%+34.2%-26.5%-
Revenue CAGR (3Y)+6.8%+1.6%+9.2%+10.6%+14.3%+16.0%+8.3%
EBITDA CAGR (3Y)+13.5%-5.7%-10.3%-3.5%+5.5%+1.1%-0.3%
Profitability & leverage
Net income margin+13.3%+10.3%+8.4%+14.3%+14.6%+14.5%+20.9%
Return on capital employed+12.5%+9.2%+11.2%+12.8%+14.6%+11.7%+17.6%
Return on net worth+8.8%+6.7%+7.9%+9.6%+11.5%+9.4%+14.4%
Debt / equity0.040.070.080.100.110.130.13
Long-term debt / equity0.020.040.050.040.040.050.05
Interest cover11.0210.2013.6513.424.535.397.25
Efficiency & per share
Fixed asset turnover1.411.501.511.822.642.252.97
Inventory turnover7.577.797.407.297.326.457.66
Debtors turnover1.651.611.521.481.681.241.18
EPS (₹)9.166.554.848.218.946.548.95
Dividend per share (₹)0.100.500.500.500.500.500.50
Book value per share (₹)109.20100.4794.4189.9682.1273.2666.21

To see the full year-wise statements and ratios of Bliss GVS Pharma Limited, buy the company report.

Board of directors and KMP of Bliss GVS Pharma Limited

Bliss GVS Pharma Limited currently reports 5 directors and 3 key managerial personnel. 16 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Shruti Vishal Rao
Also directs: GVSK LLP, Kremoint Pharma Private Limited
Whole-Time Director27 Jul 200620 Years 3 MonthsCurrent
Vibha Gagan Sharma
Also directs: GVSK LLP, Kremoint Pharma Private Limited
Whole-Time Director29 Jul 200818 Years 3 MonthsCurrent
Shilpa Bhatia
Also directs: Amj Land Holdings Limited, Aeroflex Industries Limited
Director11 Feb 20206 Years 8 MonthsCurrent
Santosh Laxman ParabDirector24 May 201610 Years 5 MonthsCurrent
Aditi Himanshu BhattCompany Secretary09 Aug 20188 Years 3 MonthsCurrent
Narsimha Shibroor Kamath
Also directs: GVSK LLP, Jayvin Developer LLP
Ceo10 Oct 20251 Years 1 MonthsCurrent
Showing 6 of 8 current directors and KMP. View all directors and KMP

Auditor

Bliss GVS Pharma Limited is audited by KALYANIWALLA & MISTRY LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
KALYANIWALLA & MISTRY LLPFY 2025104607W/W100166

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 35.00%, foreign institutional investors hold 8.10%, domestic institutional investors hold 9.40% and retail and other public shareholders hold 47.50%.

Promoters: 35.00%DII (Domestic Institutional): 9.40%FII (Foreign Institutional): 8.10%Retail & Others: 47.50%
Sep 2026
QUARTER
35.00% Promoters
9.40% DII (Domestic Institutional)
8.10% FII (Foreign Institutional)
47.50% Retail & Others
Promoter holding - history
Now 35.00% · Sep 2026High 35.40% · Dec 2025Low 35.00% · Sep 2026
34%34.8%35.5%36.3%37%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 35.40%Mar 2026: 35.40%Jun 2026: 35.40%Sep 2026: 35.00%35.40%35.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters35.00%35.40%35.40%35.40%
Public65.00%64.60%64.60%64.60%

Charges & borrowings

Open charges
₹161 Cr
Satisfied charges
₹401.25 Cr
Breakdown by lending institutions
Others₹160.00 Cr
Hdfc Bank Limited₹1.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
02 Sep 2023100791236Others₹75 CrOpen
21 Nov 2020100411042Hdfc Bank Limited₹1 CrOpen
07 Oct 200610026649Others₹85 CrOpen
16 Dec 2023100843177Others₹35 CrSatisfied
17 Sep 2021100488249Others₹65 CrSatisfied

To see the full charge records of Bliss GVS Pharma Limited, buy the company report.

Total charge records: 23 View all charges

Deals & funding

Bliss GVS Pharma Limited has 86 deals on record (85 market trades, 1 secondary share transfer); the latest was in September 2026.

Total deals
86
Market trades
85
Secondary share transfer
1

Deals on record (5 of 86)

WhenDealAmountParties
Sep 2026Secondary share transferUndisclosedBuyer: Anupam Rasayan India Limited
May 2026Market trade₹23.67 CrBuyer: Hrti Private Limited
Seller: Hrti Private Limited
Mar 2026Market trade₹13.07 CrBuyer: Hrti Private Limited
Seller: Hrti Private Limited
Mar 2026Market trade₹15.24 CrBuyer: Ratnabali Equity Private Limited
Mar 2026Market trade₹15.21 CrSeller: Ratnabali Equity Private Limited

To see the full deal history of Bliss GVS Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Bliss GVS Pharma Limited was last rated by Crisil on 19 Nov 2019.

Rating agencyRated onRating
Crisil19 Nov 2019

To see the full credit ratings and regulatory alerts of Bliss GVS Pharma Limited, buy the company report.

MSME payment delays

Bliss GVS Pharma Limited has 15 MSME Form 1 returns on record between 2019 and 2024, listing 1,629 overdue payments to 115 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 115)

SupplierAmount dueDue sinceReported on
Suprim Chemicals
an individual supplier
an individual supplier
Innovative Print Pack Private Limited
Jagatguru Printing Private Limited

To see the full MSME payment records of Bliss GVS Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Bliss GVS Pharma has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Kremoint Pharma Pvt. Ltd.U24230MH1992PTC066737

To see the full group structure of Bliss GVS Pharma Limited, buy the company report.

Employees & EPFO

Bliss GVS Pharma Limited has a workforce of 926 employees on its EPFO records as of Mar 31, 2025, across 1 active EPFO establishment.

Employee count
926
Active EPFO establishments
1
Employee growth
13.9%

GST

Bliss GVS Pharma has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AABCB1382J1ZQMaharashtraActive01 Jul 2017
24AABCB1382J2ZVGujaratActive18 Nov 2021

To see the full GST registrations and return filing status of Bliss GVS Pharma Limited, buy the company report.

Recent activity

Bliss GVS Pharma Limited has 34 board changes on record since 1984: 21 appointments and 13 cessations. The latest: Gagan Harsh Sharma ceased to be Managing Director on 06 Nov 2025.

Filing
Bliss Gvs Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge registered on 17 Sep 2021 via Charge ID 100488249 with Others was fully satisfied on 30 Mar 2026.
Charges
A charge registered on 16 Dec 2023 via Charge ID 100843177 with Others was fully satisfied on 09 Jan 2026.
Ceased
Gagan Harsh Sharma ceased to be Managing Director.
Appointed
Narsimha Shibroor Kamath was appointed as CEO.
AGM
Bliss Gvs Pharma Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records.
Charges
A charge with Others of Rs. 75.00 Cr registered on 02 Sep 2023 with Charge ID 100791236 was modified on 30 Jan 2025.
Ceased
Subramanian Ramaswamy Vaidya ceased to be Director.
Appointed
Nandkumar Kashinath Chodankar was appointed as Director.
Charges
A charge with Others of Rs. 35.00 Cr registered on 16 Dec 2023 with Charge ID 100843177 was modified on 22 Dec 2023.
Charges
A charge with Others amounted to Rs. 35.00 Cr with Charge ID 100843177 was registered on 16 Dec 2023.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 100791236 was registered on 02 Sep 2023.

81 earlier events are in the company report.

News

BLISSGVS: Q2 REVENUE 3.13B RUPEES VS 2.4B (YOY)
29 Oct 2026 · Exchange Update
BLISSGVS: Q2 CONS NET PROFIT 522.5M RUPEES VS 273M (YOY)
29 Oct 2026 · Exchange Update
BLISSGVS: Q2 EBITDA 806M RUPEES VS 308M (YOY); Q2 EBITDA MARGIN 25.71% VS 12.58% (YOY)
29 Oct 2026 · Exchange Update

Frequently asked questions

Bliss GVS Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 December 1984 (42+ years old) and is registered under CIN L24230MH1984PLC034771. Listed on BSE: 506197 and NSE: BLISSGVS.

Bliss GVS Pharma reported revenue of ₹927.11 Cr for FY 2025-26 (up 14.5% YoY) based on consolidated financials.

Bliss GVS Pharma has 8 current directors and KMP:

The latest financial statements of Bliss GVS Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Bliss GVS Pharma is 27AABCB1382J1ZQ, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 24AABCB1382J2ZV (Gujarat).

The CIN (Corporate Identification Number) of Bliss GVS Pharma is L24230MH1984PLC034771. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Bliss GVS Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 506197) and NSE (symbol: BLISSGVS).

Bliss GVS Pharma has 51 court cases on record: 12 filed by the company and 39 filed against it. 20 are pending. Most are in the district courts.

Bliss GVS Pharma was incorporated on 11 December 1984, making it 42+ years old. It is registered with the Registrar of Companies, Mumbai.

Bliss GVS Pharma has 86 deals on record (85 market trades, 1 secondary share transfer); the latest was in September 2026.

Gagan Harsh Sharma ceased to be Managing Director on 06 Nov 2025. Narsimha Shibroor Kamath was appointed as CEO on 10 Oct 2025. Subramanian Ramaswamy Vaidya ceased to be Director on 27 Aug 2024. Bliss GVS Pharma has 34 board changes on record in total.